Navigation Links
BD to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
Date:6/3/2011

FRANKLIN LAKES, N.J., June 3, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Thursday, June 9, 2011, at 11:00 am (ET).

A live webcast of BD's presentation can be accessed from the BD corporate website at www.bd.com/investors and will be available for replay through Thursday, June 16, 2011.    

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5378
Colleen T. White, Corporate Communications – 201-847-5369


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014  A new global ... finds that a large majority of the general public ... (84%), a devastating disease that is responsible for 1.59 ... cancers combined 1,2,4 . The "Any One Any Lung" ... about the widespread impact of lung cancer, but also ...
(Date:11/18/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... receipt of approval from the U.S. Food and Drug ... IMPLANT ® Saline-filled Breast Implant for ... augmentation implants. The FDA approval of the IDEAL IMPLANT ... and data including a U.S. clinical trial that began ...
(Date:11/18/2014)... Tocagen Inc. today announced that ... free survival at six months for recurrent high grade ... FC, compared to published benchmarks. HGG includes glioblastoma, the ... The data were delivered in an oral presentation at the ... of the Society for Neuro-Oncology (SNO) by Tim ...
Breaking Medicine Technology:Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 2Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 3Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 4Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 5Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 6Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 2Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 4Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 5
... May 16 Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO.OB) ... Phase I Human Trials with its PulmoBind Molecular Imaging,technology ... The work will be carried out by the Pulmo ... is: "Phase I Study of the Use,of PulmoBind for ...
... -- Results demonstrating that TYKERB and trastuzumab ... survival (PFS), -- Combining TYKERB and trastuzumab ... HER2 receptor may create a more complete HER2 ... alone despite patients,previous treatment with multiple lines of ...
Cached Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7
(Date:11/18/2014)... 18, 2014 Cristcot Inc., a ... and commercialization of specialized drug delivery systems, today ... Cristcot a patent for the technology, which encompasses ... , The patent was awarded to the ... have been assigned to Cristcot Inc. The patented ...
(Date:11/18/2014)... 18, 2014 Medicationdiscountcard.com's ... adding to the company's reputation for helping consumers ... blog has to offer at http://blog.medicationdiscountcard.com/ . ... information concerning the Affordable Care Act and the ... inform the public about a variety of prescription ...
(Date:11/18/2014)... Thompson HealthDay Reporter ... antibody drug could prove effective at lowering LDL ("bad") ... cholesterol-lowering statin medications. That,s the conclusion of a ... annual meeting in Chicago. The drug, alirocumab, outperformed ... used alternative to statins, Zetia, said lead researcher Dr. ...
(Date:11/18/2014)... (HealthDay News) -- Women who started smoking at a ... severe menstrual pain, a new study suggests. About ... smoking has been suspected as a risk factor for ... authors of the new study said. The researchers ... long-term study of women,s health in Australia. About 14 ...
(Date:11/18/2014)... November 18, 2014 Global ... using the telehealth platform to bring quality healthcare ... this passion, GPT created Global Partnership for TeleHealth ... already existing telehealth network. GPTM focuses specifically ... overseas, and disaster relief organizations. , ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2
... from Shropshire and parts of Wales. Breast cancer patients from ... but Welsh women get it for free. // ,This ... to pay for Herceptin for early stage breast cancer sufferers ... the welsh as all Welsh Local Health Boards have agreed ...
... in the capital of Zagreb it was revealed that a dead ... flu virus. //, ,The location of the dead swan was ... weekend. Tests confirmed that the dead bird had contracted the H5 ... it was the lethal H5N1 strain would be released on Sunday ...
... simulated investment game, a study, intending to investigate ... working //collectively in a team, revealed stark observations ... conducted by the University of Erfurt team, found ... when ‘punishments’ became a form of motivation. Psychologists ...
... nations should be prepared to pledge more money to combat ... ,Western and Asian donors had pledged $1.9 billion ... flu and improve containment and prevention methods in 12 countries, ... spreading across the world through migratory birds, including infections in ...
... should avoid exposure to the fumes of solvents used ... and lacquers//, could give rise to allergies in young ... Germany's environmental agency. ,Pregnant women should leave ... stay clear of the work area altogether. ...
... has warned the nation's betel-nut chewers of the increased ... habits like smoking and drinking. ,According to ... National Health Research Institute when betel nut chewing was ... cancer of the esophagus was about 195 times higher ...
Cached Medicine News:Health News:Free Herceptin Treatment for Those Who Live Over the Welsh Border 2Health News:Motivation Yardstick: Rewards or Punishment? Discover the Superior Performance Trigger 2Health News:Cancer Risks for Betel Nut Chewers 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: